Skip to main content

Advertisement

Table 5 Acute adverse events in 59 patients

From: Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial

Adverse events No. (%) of patients by toxicity grade during ICT No. (%) of patients by toxicity grade during CRT
1 2 3 4 1 2 3 4
Hematological
 Anemia 28(47.5) 4(6.8) 0(0) 0(0) 22(37.3) 13(22.0) 10(16.9) 0(0)
 Neutropenia 17(28.8) 17(28.8) 4(6.8) 1(1.7) 13(22.0) 22(37.3) 13(22.0) 2(3.4)
 Leucopenia 20(33.9) 14(23.7) 4(6.8) 0(0) 14(23.7) 20(33.9) 20(33.9) 0(0)
 Thrombocytopenia 9(15.3) 10(16.9) 3(5.1) 0(0) 4(6.8) 20(33.9) 16(27.1) 8(13.6)
 Days of grade 3 or greater thrombocytopenia      ≤7 8-14 ≥15  
     17(28.8) 6(10.2) 1(1.7)  
Non-hematological
 Allergy 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)
 Weight loss 5(8.5) 0(0) 0(0) 0(0) 33(55.9) 5(8.5) 0(0) 0(0)
 Stomatitis (mucositis) 2(3.4) 1(1.7) 1(1.7) 0(0) 49(83.1) 8(13.6) 2(3.4) 0(0)
 Nausea 21(35.6) 2(3.4) 0(0) 0(0) 14(23.7) 6(10.2) 0(0) 0(0)
 Vomiting 9(15.3) 2(3.4) 0(0) 0(0) 7(11.9) 6(10.2) 0(0) 0(0)
 Diarrhea 1(1.7) 0(0) 0(0) 0(0) 1(1.7) 0(0) 0(0) 0(0)
 Hepatotoxicity 21(35.6) 3(5.1) 2(3.4) 0(0) 23(39.0) 3(5.1) 2(3.4) 0(0)
 Nephrotoxicity 10(16.9) 0(0) 0(0) 0(0) 11(18.6) 0(0) 0(0) 0(0)
 Cardiotoxicity 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)
 Ototoxicity 0(0) 0(0) 0(0) 0(0) 10(16.9) 0(0) 0(0) 0(0)
 Neurotoxicity 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)
 Joint and muscular ache 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)
 Alopecia 1(1.7) 0(0) 0(0) 0(0) 59(100) 0(0) 0(0) 0(0)
  1. Abbreviation ICT induction chemotherapy; CRT concurrent chemoradiotherapy